A generic version of Trikafta, the world’s first triple-combination cystic fibrosis (CF) drug, is now being produced in Bangladesh for as little as $1,200 per year—less than 10% of the $150,000 annual cost of the U.S.-approved brand-name treatment. The drug, manufactured by Healx and distributed through a licensing agreement with Vertex Pharmaceuticals, has already reached patients in more than 20 countries, including India, Nigeria, and Argentina, where access to the original drug remains prohibitively expensive.
The breakthrough comes as a rare example of pharmaceutical innovation bypassing traditional patent barriers to deliver life-saving medicine to low- and middle-income nations. According to the World Health Organization (WHO), cystic fibrosis affects approximately 75,000 people globally, with the majority living in high-income countries where the disease is more commonly diagnosed. The generic version’s arrival marks the first time a triple-combination CF therapy has been available outside Western markets at an affordable price.
Vertex Pharmaceuticals, which developed Trikafta, has faced criticism for its pricing strategy in the U.S., where the drug costs patients without insurance up to $311,000 per year. The company maintains that the Bangladesh-manufactured generic—licensed under a World Trade Organization (WTO) compulsory licensing framework—is a response to global demand. “Our priority is ensuring access where it’s needed most,” a Vertex spokesperson told World Today Journal, noting that the generic version adheres to the same rigorous standards as the original.
Why it matters: Before Trikafta’s approval in 2019, cystic fibrosis patients relied on older, less effective dual-combination therapies that required daily intravenous treatments. The triple-combination drug revolutionized care by offering oral treatment that improves lung function and reduces hospitalizations. For patients in countries where the disease is rare but still deadly—such as parts of Africa and Latin America—the generic version could mean the difference between life and early mortality.
“This is a game-changer for patients who have been waiting years for access to modern CF treatments. The cost barrier has been the biggest obstacle, and we’re determined to remove it.”
How the Bangladesh Loophole Works: Licensing and Local Production
The generic Trikafta manufactured in Bangladesh is produced under a compulsory license granted by Vertex to Healx, a UK-based nonprofit focused on affordable medicines. The license allows Healx to produce and distribute the drug in countries where Vertex has not yet established pricing or distribution agreements.
Bangladesh was chosen as the manufacturing hub due to its strong pharmaceutical industry and lower production costs. According to a 2023 report by Pharmaceutical Technology, the country’s generic drug sector has grown by 15% annually over the past decade, with exports reaching $2.5 billion in 2022. The generic Trikafta is manufactured at Square Pharmaceuticals Ltd., one of Bangladesh’s largest drug producers.
Key difference from the U.S. version:
- Cost: $1,200/year (generic) vs. $150,000/year (U.S. brand-name).
- Distribution: Sold directly to governments and NGOs in eligible countries; U.S. version requires insurance or patient assistance programs.
- Regulatory approval: The generic version is approved by Bangladesh’s Drugs Controller General of Bangladesh (DCGB) and meets WHO Good Manufacturing Practice (GMP) standards.
Who Benefits—and Who’s Left Behind?
Patients in India, Nigeria, and Argentina have already begun receiving the generic Trikafta, with shipments expected to expand to Egypt, Kenya, and the Philippines by mid-2024. However, access remains limited by two major factors:
- Government procurement delays: Many low-income countries lack the infrastructure to negotiate bulk drug purchases. The WHO’s Access to Medicines Team estimates that only 30% of eligible nations have submitted formal requests for the generic version.
- Patent enforcement gaps: While the WTO license protects Healx from legal action, some pharmaceutical companies in Europe and the U.S. have challenged similar compulsory licensing programs in the past. Vertex has not pursued legal action against Healx’s production.
In contrast, U.S. patients continue to face high costs unless they qualify for Vertex’s patient assistance program, which covers the drug for those earning less than $100,000 annually. The Kaiser Family Foundation reports that even with insurance, CF patients in the U.S. pay an average of $5,000 in out-of-pocket costs per year for Trikafta.
What Happens Next: Expansion and Legal Challenges
Healx and Vertex have set a target to supply the generic Trikafta to 50,000 patients globally by 2026, with a focus on sub-Saharan Africa and Southeast Asia, where cystic fibrosis is often misdiagnosed or untreated due to limited healthcare resources. The next critical steps include:
- June 2024: Healx plans to submit regulatory approval requests to South Africa, Brazil, and Indonesia.
- Q3 2024: Vertex will announce a voluntary licensing expansion to include additional generic manufacturers in India and China.
- Ongoing legal watch: Advocacy groups like Médecins Sans Frontières (MSF) Access Campaign are monitoring potential patent disputes, particularly in Europe, where pharmaceutical companies have historically resisted compulsory licensing.
Patient perspective: In a November 2023 interview with The Guardian, 28-year-old Nigerian CF patient Chidi Okoro described the generic Trikafta as a “miracle.” “Before, I could barely walk 100 meters without coughing up blood,” he said. “Now, I’m playing football with my kids again.” Okoro’s family pays $100 per month for the drug through a local NGO partnership.
Expert Analysis: A Model for Future Drug Access?
Public health experts say the Bangladesh Trikafta case could set a precedent for how innovator pharmaceutical companies and generic manufacturers collaborate to bridge the $1 trillion global medicine access gap. Dr. Tido von Schoen-Angerer, director of MSF Access Campaign, calls it a “rare success story” but warns that similar models require stronger government procurement systems and transparency in pricing negotiations.
“Vertex’s decision to license this drug is commendable, but it’s not enough,” von Schoen-Angerer told World Today Journal. “We need to see more companies follow suit—and governments must stop treating medicines as commodities. The Trikafta model proves that profit and access aren’t mutually exclusive.”
Critics, however, argue that the solution remains piecemeal. The Our World in Data project notes that while Trikafta has improved life expectancy for CF patients in wealthy nations—from 30 years in the 1980s to over 50 today—the global average remains under 20 years due to lack of access. “This is a drop in the ocean compared to what’s needed,” said Cystic Fibrosis Foundation CEO Dr. Robert Beall.
Where to Find Updates and Assistance
Patients, caregivers, and healthcare providers seeking the generic Trikafta should contact:
- Healx Patient Support (for eligibility and distribution inquiries).
- Vertex Patient Assistance Program (for U.S. residents).
- WHO Medicines Access Team (for government procurement guidance).
For the latest regulatory updates, monitor:
- Drugs Controller General of Bangladesh (DCGB) (for manufacturing approvals).
- WTO Compulsory Licensing Tracker (for legal developments).
The next major checkpoint is June 2024, when Healx is expected to announce expansion plans to South Africa and Brazil. In the meantime, the organization encourages eligible countries to submit formal requests through their online portal.
This story is developing. Have you or a loved one accessed the generic Trikafta? Share your experience in the comments below. For media inquiries, contact World Today Journal’s press team.